Molecularly Targeted Therapies in Non-small-cell Lung Cancer Annual Update 2014

Overview

Journal J Thorac Oncol

Publisher Elsevier

Specialties Oncology
Pulmonary Medicine

Date 2014 Dec 24

PMID 25535693

Citations 60

Authors

Daniel Morgensztern

Meghan J Campo

Suzanne E Dahlberg

Robert C Doebele

Edward Garon

David E Gerber

Sarah B Goldberg

Peter S Hammerman

Rebecca S Heist

Thomas Hensing

Leora Horn

Suresh S Ramalingam

Charles M Rudin

Ravi Salgia

Lecia V Sequist

Alice T Shaw

George R Simon

Neeta Somaiah

David R Spigel

John Wrangle

David Johnson

Roy S Herbst

Paul Bunn

Ramaswamy Govindan

Affiliations

Soon will be listed here.

Abstract

There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC. We are beginning to understand the mechanisms of acquired resistance after exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next-generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy.

Citing Articles

Aidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway.

Zhang J, Yang S, Chen X, Zhang F, Guo S, Wu C Chin Med. 2025; 20(1):2.

PMID: 39754146 PMC: 11699780. DOI: 10.1186/s13020-024-01054-1.

Assessing the benefits and safety profile of incorporating poly ADP-ribose polymerase (PARP) inhibitors in the treatment of advanced lung cancer: a thorough systematic review and meta-analysis.

Tang M, Wang Y, Li P, Han R, Wang R Front Pharmacol. 2024; 15:1338442.

PMID: 38989152 PMC: 11234112. DOI: 10.3389/fphar.2024.1338442.

Dacomitinib exhibits promising activity against the rare exon 20 insertion M774delinsWLV in lung cancer: A case report and literature review.

Yang G, Liu R, Tang X Heliyon. 2024; 10(9):e30312.

PMID: 38707278 PMC: 11068806. DOI: 10.1016/j.heliyon.2024.e30312.

Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy.

Kim S, Lee Y, Song B, Sim H, Kang E, Hwang M Cancers (Basel). 2024; 16(4).

PMID: 38398169 PMC: 10887363. DOI: 10.3390/cancers16040778.

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).

Yang G, Xu H, Yang Y, Zhang S, Xu F, Hao X BMC Med. 2022; 20(1):277.

PMID: 36031613 PMC: 9422117. DOI: 10.1186/s12916-022-02470-6.

References

Okamoto K, Kodama K, Takase K, Sugi N, Yamamoto Y, Iwata M . Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013; 340(1):97-103. DOI: 10.1016/j.canlet.2013.07.007. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Mitsudomi T, Viallet J, Mulshine J, Linnoila R, Minna J, Gazdar A . Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991; 6(8):1353-62. View

Nishino M, Dahlberg S, Cardarella S, Jackman D, Rabin M, Ramaiya N . Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer. 2013; 119(21):3761-8. PMC: 3817609. DOI: 10.1002/cncr.28290. View

Tran T, Selinger C, Kohonen-Corish M, McCaughan B, Kennedy C, OToole S . Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer. 2013; 81(3):462-467. DOI: 10.1016/j.lungcan.2013.05.015. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Malchers F, Dietlein F, Schottle J, Lu X, Nogova L, Albus K . Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov. 2013; 4(2):246-57. DOI: 10.1158/2159-8290.CD-13-0323. View

Arcila M, Chaft J, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M . Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012; 18(18):4910-8. PMC: 3865806. DOI: 10.1158/1078-0432.CCR-12-0912. View

10.

Azad N, Zahnow C, Rudin C, Baylin S . The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol. 2013; 10(5):256-66. PMC: 3730253. DOI: 10.1038/nrclinonc.2013.42. View

11.

Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H . A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006; 95(8):998-1004. PMC: 2360715. DOI: 10.1038/sj.bjc.6603393. View

12.

Singh D, Chan J, Zoppoli P, Niola F, Sullivan R, Castano A . Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012; 337(6099):1231-5. PMC: 3677224. DOI: 10.1126/science.1220834. View

13.

Westcott P, To M . The genetics and biology of KRAS in lung cancer. Chin J Cancer. 2012; 32(2):63-70. PMC: 3845615. DOI: 10.5732/cjc.012.10098. View

14.

Wesche J, Haglund K, Haugsten E . Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437(2):199-213. DOI: 10.1042/BJ20101603. View

15.

Ma P, Jagadeeswaran R, Jagadeesh S, Tretiakova M, Nallasura V, Fox E . Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005; 65(4):1479-88. DOI: 10.1158/0008-5472.CAN-04-2650. View

16.

Seo J, Ju Y, Lee W, Shin J, Lee J, Bleazard T . The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012; 22(11):2109-19. PMC: 3483540. DOI: 10.1101/gr.145144.112. View

17.

Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S . RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18(3):378-81. DOI: 10.1038/nm.2658. View

18.

Sholl L, Sun H, Butaney M, Zhang C, Lee C, Janne P . ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol. 2013; 37(9):1441-9. PMC: 3831351. DOI: 10.1097/PAS.0b013e3182960fa7. View

19.

Hoos A, Eggermont A, Janetzki S, Hodi F, Ibrahim R, Anderson A . Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010; 102(18):1388-97. PMC: 2943524. DOI: 10.1093/jnci/djq310. View

20.

Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P . Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013; 3(6):630-5. PMC: 4160032. DOI: 10.1158/2159-8290.CD-13-0035. View